US Treasury 3 Year Note ETF UTRE 深 滬
交易中 11-07 10:46:24 美东时间
49.815
0.000
0.00%
華盛通- 最 高49.81
- 今 開49.81
- 成交量 238股
- 最 低 49.81
- 昨 收 49.815
- 總市值 1046.12万
- 52周最高 49.9346
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 47.0822
- 委 比 75.00%
- 總股本 21.00万
- 歷史最高 49.9346
- 量 比 2.13
- 振 幅 0.00%
- 歷史最低 44.1921
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Next: Liquidia's Earnings Preview
Liquidia (NASDAQ:LQDA) is set to give its latest quarterly earnings report on M...
11-01 00:03
Merus Announces Interim Clinical Data From Ongoing Phase 2 Trial Of Bispecific Antibody Petosemtamab In Metastatic Colorectal Cancer In Combination With FOLFOX/FOLFIRI
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct.
10-24 22:04
Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific
10-14 00:04
XOMA Royalty And LAVA Therapeutics Announced The Extension Of The Expiration Of The Tender Offer To Purchase All Outstanding Shares Of Common Shares Of LAVA
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today
10-03 04:47
Liquidia Analysts Raise Their Forecasts Following Q2 Results
Liquidia Corporation (NASDAQ:LQDA) reported a loss for the second quarter on Tu...
08-14 02:51
In July And August Of 2025, Liquidia Analyzed Interim Data From The 52-week, Prospective, Open-label ASCENT Study Which Fully Enrolled 54 Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints. The tolerability profile of YUTREPIA in PH-ILD was consistent with initial observations in the first 20 patients
08-12 18:36
Earnings Preview For Liquidia
Liquidia (NASDAQ:LQDA) is gearing up to announce its quarterly earnings on Tues...
08-11 23:04
Liquidia Begins Shipping Newly Approved Yutrepia for Rare Lung Diseases Just Days After FDA OK
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial
06-02 18:34
Breaking Down Liquidia: 12 Analysts Share Their Views
During the last three months, 12 analysts shared their evaluations of Liquidia ...
05-28 21:00
Liquidia Technologies Gains FDA Approval for YUTREPIA
Liquidia Technologies ( ($LQDA) ) has provided an announcement. On May 23, 2025...
05-24 04:52
